

**Louisiana Department of Health  
Medicaid Pharmaceutical and Therapeutics Committee  
TOP\$ Virtual Review  
Via Videoconferencing  
November 3, 2021  
9:00 AM  
DRAFT**

- I. Call to Order.....Marty McKay
- II. Parliamentary Business .....Marty McKay
  - A. Introduction of Members/Roll Call
- III. P & T Committee Review Virtual Process.....Hind Douiki/Melwyn Wendt
- IV. Reports.....Melwyn Wendt
  - A. PDL Reflecting Spring 2021 Recommendations
- V. New Business.....Hind Douiki
  - A. Explanation of TOP\$, Monographs and Cost Sheet
  - B. Therapeutic Class Reviews of Drug Classes/Drug Manufacturer Testimony/Public Testimony
    - 1. Alzheimer’s Agents
    - 2. Anthelmintics
    - 3. Anti-Allergens, Oral
    - 4. Anticonvulsants
    - 5. Antidepressants, Other
    - 6. Antidepressants, SSRIs
    - 7. Antihistamines, Minimally Sedating
    - 8. Antihypertensives, Sympatholytics
    - 9. Antihyperuricemics
    - 10. Antiparkinson’s Agents
    - 11. Antipsoriatics, Oral
    - 12. Antipsoriatics, Topical
    - 13. Antipsychotics
    - 14. Anxiolytics
    - 15. Bile Salts
    - 16. Botulinum Toxins
    - 17. Bronchodilators, Beta Agonist
    - 18. Colony Stimulating Factors
    - 19. COPD Agents
    - 20. Cytokine and CAM Antagonists
    - 21. Emollients
    - 22. Enzyme Replacement, Gauchers Disease
    - 23. Epinephrine, Self-Injected

24. Erythropoiesis Stimulating Proteins
25. Glucocorticoids, Inhaled
26. Glucocorticoids, Oral
27. Hemophilia Treatment
28. Histamine II Receptor Blocker
29. Idiopathic Pulmonary Fibrosis
30. Immune Globulins
31. Immunomodulators, Asthma
32. Immunomodulators, Atopic Dermatitis
33. Immunomodulators, Lupus - **New**
34. Immunomodulators, Topical
35. Intranasal Rhinitis Agents
36. Leukotriene Modifiers
37. Methotrexate
38. Movement Disorders
39. Neuropathic Pain
40. NSAIDs
41. Oncology Oral – Breast
42. Oncology Oral – Hematologic
43. Oncology Oral - Lung
44. Oncology Oral – Other
45. Oncology Oral – Prostate
46. Oncology Oral – Renal Cell
47. Oncology Oral - Skin
48. Ophthalmic Antibiotics
49. Ophthalmic, Antibiotic-Steroid Combinations
50. Ophthalmics for Allergic Conjunctivitis
51. Ophthalmics, Anti-Inflammatory
52. Ophthalmics, Anti-Inflammatory/ Immunomodulator
53. Ophthalmics, Cystinosis - **New**
54. Ophthalmics, Glaucoma Agents
55. Otic Antibiotics
56. Otic Anti-Infectives & Anesthetics
57. Progestational Agents
58. Sedative Hypnotics
59. Sickle Cell Anemia Treatments
60. Smoking Cessation
61. Steroids, Topical High
62. Steroids, Topical Low
63. Steroids, Topical Medium
64. Steroids, Topical Very High
65. Stimulants and Related Agents
66. Thrombopoiesis Stimulating Proteins

VI.	New & Other Single Drug Reviews.....	Hind Douiki
	67. Antifungals, Oral - Brexafemme®	

- 68. Bladder Relaxant Preparations – Myrbetriq<sup>®</sup> Granules
- 69. Glucagon Agents – Zegalogue<sup>®</sup> Syringe
- 70. Glucagon Agents – Zegalogue<sup>®</sup> Autoinjector
- 71. Multiple Sclerosis Agents – Ponvory<sup>®</sup> Starter Pack
- 72. Multiple Sclerosis Agents – Ponvory<sup>®</sup> Tablet
- 73. Opiate Dependence Treatments – Kloxxado<sup>®</sup> Spray
- 74. Phosphate Binders – Magnebind<sup>®</sup> 400 RX
- 75. Uterine Disorder Treatments - Myfembree<sup>®</sup>

VII. Other Business

VIII. Next Steps

- A. Proposed Therapeutic Classes to be Reviewed at Next Meeting

IX. Next Meeting Date – Friday, April 29, 2022 or Friday, May 6, 2022

X. Public Testimony